Former Director of the Office of National Drug Control Policy to Moderate
First Educational Webinar: When Good Medicines Become Bad Drugs
FRAZER, Pa., Oct. 14 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq:
CEPH) announced today that it is embarking on a national educational
program designed to promote greater awareness among patients, caregivers
and the public about the importance of appropriate and responsible use of
prescription opioid medications. The initiative, When Good Medicines Become
Bad Drugs(SM), will include a series of free educational programs on timely
topics. The first webcast, moderated by General Barry R. McCaffrey, former
Director of the Office of National Drug Control Policy, will take place on
Tuesday, October 21, 2008, from 3:00 p.m. - 4:00 p.m. Eastern, and will
focus on safeguarding medications in the home.
"This program is consistent with Cephalon's commitment to ensure that
prescription medications are used safely by the appropriate patients," said
Dr. Lesley Russell, Executive Vice President and Chief Medical Officer at
Cephalon. "Currently, 71 percent of people who abuse prescription pain
medicines received them from a friend or family member, not through a
doctor's prescription. The aim of this program is to heighten patient and
public awareness of, and responsibility for, safeguarding the use of these
important medications."
About When Good Medicines Become Bad Drugs Webcast
This free webcast will provide practical tips about what patients,
caregivers and the public can do to safeguard medications and help prevent
abuse and diversion of prescription opioids. The webcast will take place on
October 21, 2008, from 3:00 p.m. - 4:00 p.m. Eastern. Participants can
register at http://video.webcasts.com/events/vxmd001/28151/.
Panelists will include:
Moderator: General Barry R. McCaffrey, former Director of the Office of
National Drug Control Policy
Jeff Gudin, M.D., Co-Director of the Pain Management Center at
Englewood Hospital and Medical Center in New Jersey
Steve Passik, Ph.D., Associate Attending Psychologist at Memorial
Sloan-Kettering Cancer Center in New York
Jennifer Bolen, J.D., a patient living with chronic pain and founder of
The Legal Side of Pain, a Tennessee-based organization that provides legal
guidance regarding use of pain medications
Cephalon, Inc.
Founded in 1987, Cephalon, Inc. is an international biopharmaceutical
company dedicated to the discovery, development and commercialization of
innovative products in four core therapeutic areas: central nervous system,
pain, oncology and addiction. A member of the Fortune 1000, Cephalon
currently employs approximately 3,000 people in the United States and
Europe. U.S. sites include the company's headquarters in Frazer,
Pennsylvania, and offices, laboratories or manufacturing facilities in West
Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis,
Minnesota. The company's European headquarters are located in
Maisons-Alfort, France.
The company's proprietary products in the United States include:
TREANDA(R) (bendamustine hydrochloride) for Injection, AMRIX(R)
(cyclobenzaprine hydrochloride extended-release capsules), PROVIGIL(R)
(modafinil) Tablets [C-IV], FENTORA(R) (fentanyl buccal tablet) [CII],
TRISENOX(R) (arsenic trioxide) injection, VIVITROL(R) (naltrexone for
extended-release injectable suspension), GABITRIL(R) (tiagabine
hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral
transmucosal fentanyl citrate) [C-II]. The company also markets numerous
products internationally. Full prescribing information on its U.S. products
is available at http://www.cephalon.com or by calling 1-800-896-5855.
SOURCE Cephalon, Inc.
 back to top
Related links:
http://www.cephalon.com
http://video.webcasts.com/events/vxmd001/28151
CONTACT:
Stacey Beckhardt of Cephalon, Inc.,
+1-610-738-6198, office, or +1-610-247-0212, cell,
sbeckhar@cephalon.com
|
